A Phase 3 interventional study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria, sponsored by Alexion Pharmaceuticals, Inc.. Completed at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal — none open to participants now, none under way, none of them phase 3. eculizumab · Hemoglobinuria, Paroxysmal.
Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, this one is the 14th largest by enrollment, is the only one that started in 2023, is one of 14 in phase 3, and was the 16th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →None of the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal is open now. The open studies under Hemoglobinuria, Paroxysmal, anywhere →
eculizumab: first FDA approval 2007 (SOLIRIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2023.
This study's enrollment of 25 is below the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 37 across the 18 interventional studies. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 18 have an industry lead sponsor. The 8 most frequent:
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca: 3 open now, 7 under way, 2 of them phase 3. Of 26 finished, 18 (69%) have results posted.
Among the 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca, this one is the 13th largest by enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2023, is one of 12 in phase 3, and was the 26th registered.
AstraZeneca’s Hemoglobinuria, Paroxysmal studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing eculizumab in Hemoglobinuria, Paroxysmal, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 35 in Hemoglobinuria, Paroxysmal:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 3b, single-arm, open-label, multicenter study to evaluate the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of eculizumab in adult participants with paraxysmal noturnal hemoglobinuria (PNH) in China.
This is a Phase 3b, single-arm, open-label, multicenter study to evaluate the efficacy, safety, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of eculizumab in adult participants with PNH in China who previously have not been treated with complement inhibitors. Approximately 25 eligible participants in China will be enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Eculizumab will be administered by IV infusion.
Drug: Eculizumab
Participants will receive 600 milligrams (mg) once a week on Day 1, 8, 15, and 22 followed by 900 mg every 2 weeks from Day 29 to Day 435.
Percentage Change From Baseline in LDH at Week 12
Blood samples were collected for measurement of serum LDH at specified timepoints. Statistical analysis was performed using a mixed model for repeated measures (MMRM), including the percentage change from baseline of LDH at the scheduled visits from Week 1 to Week 12 as the dependent variable, with the fixed categorical effect of visit, fixed continuous effect of LDH baseline value as covariates, and participant as random effect. Assessed at baseline, 1, 2, 3, 4, 6, 8, 10, and 12 weeks, Week 12 reported. A decrease indicated a reduction in disease activity.
Time frame: Baseline, Week 12
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that did not necessarily have to have a causal relationship with the study intervention. A TEAE was any AE that started during or after the first infusion of the study intervention. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
Time frame: Baseline through Week 64
Serum Concentration of Eculizumab
Blood samples were collected for measurement of serum concentrations of eculizumab at specified timepoints. No study intervention administered on Day 449. Results reported as micrograms/milliliter (ug/mL).
Time frame: Day 1, Day 29, Day 85, Day 169, Day 253, Day 337, Day 421, Day 449
Change From Baseline in Serum Free Complement 5 (C5) Concentration
Blood samples were collected for measurement of serum concentration of free C5 at specified timepoints. No study intervention administered on Day 449. A decrease indicated a reduction in disease activity.
Time frame: Day 1, Day 29, Day 85, Day 169, Day 253, Day 337, Day 421, Day 449
Change From Baseline in Serum Total C5 Concentration
Blood samples were collected for measurement of serum concentration of total C5 at specified timepoints. No study intervention administered on Day 449. A decrease indicated a reduction in disease activity.
Time frame: Day 1, Day 29, Day 85, Day 169, Day 253, Day 337, Day 421, Day 449
Number of Participants With Treatment-emergent Antidrug Antibodies (ADAs) to Eculizumab
Blood samples were collected for measurement of treatment-emergent ADAs to eculizumab at specified timepoints.
Time frame: Baseline through Week 64
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 12
The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. The FACIT-Fatigue scale is a collection of quality of life (QoL) questionnaires pertaining to the management of fatigue symptoms due to a chronic illness. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores were calculated as the sum from all 13 items and ranged from 0 to 52, with higher scores indicating an increased QoL. Analysis was performed using a MMRM, including FACIT-Fatigue score change from baseline values at the scheduled visits from Week 1 to Week 12 as the dependent variable, with the fixed categorical effect of study visit, fixed continuous effect of baseline value of FACIT-Fatigue, and participant as random effect. Assessed at baseline, 1, 2, 3, 4, 6, 8, 10, and 12 weeks, Week 12 reported.
Time frame: Baseline, Week 12
Percentage of Participants With Breakthrough Hemolysis
Breakthrough hemolysis was defined as at least 1 new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, shortness of breath \[dyspnea\], anemia \[hemoglobin \<10 grams/deciliter\], major adverse vascular event \[including thrombosis\], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2 times (\*) upper limit of normal (ULN), after prior LDH reduction to \<1.5\* ULN on therapy.
Time frame: Baseline through Week 12
Percentage of Participants Achieving LDH Normalization
Blood samples were collected for measurement of LDH at specified timepoints. LDH normalization was defined as LDH ≤ULN.
Time frame: Baseline through Week 12
Percentage of Participants Achieving Transfusion Avoidance
Transfusion avoidance was defined as remaining transfusion free (that is, had not received any transfusion) and did not require transfusion as per protocol.
Time frame: Baseline through Week 12
Percentage of Participants With LDH ≤1.5* ULN at Week 12
Blood samples were collected for measurement of LDH at specified timepoints.
Time frame: Baseline through Week 12
| Milestone | Eculizumab |
|---|---|
| Started | 25 |
| Received at least 1 dose of study drug | 25 |
| Completed | 25 |
| Not completed | 0 |
| Milestone | Eculizumab |
|---|---|
| Started | 25 |
| Received at least 1 dose of study drug | 25 |
| Completed | 20 |
| Not completed | 5 |
| Withdrew: Adverse event | 1 |
| Withdrew: Other than specified | 1 |
| Withdrew: Withdrawal by subject | 3 |
Blood samples were collected for measurement of serum LDH at specified timepoints. Statistical analysis was performed using a mixed model for repeated measures (MMRM), including the percentage change from baseline of LDH at the scheduled visits from Week 1 to Week 12 as the dependent variable, with the fixed categorical effect of visit, fixed continuous effect of LDH baseline value as covariates, and participant as random effect. Assessed at baseline, 1, 2, 3, 4, 6, 8, 10, and 12 weeks, Week 12 reported. A decrease indicated a reduction in disease activity.
| percentage change | Eculizumab |
|---|---|
| Percentage Change From Baseline in LDH at Week 12 | -76.5 (-87.8 to -65.2) |
An adverse event (AE) was any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that did not necessarily have to have a causal relationship with the study intervention. A TEAE was any AE that started during or after the first infusion of the study intervention. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.
| Participants | Eculizumab |
|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 23 |
Blood samples were collected for measurement of serum concentrations of eculizumab at specified timepoints. No study intervention administered on Day 449. Results reported as micrograms/milliliter (ug/mL).
| ug/mL | Eculizumab |
|---|---|
| Day 1 | 248.81 ± 22.6 |
| Day 29 | 491.96 ± 31.3 |
| Day 85 | 507.62 ± 33.8 |
| Day 169 | 479.04 ± 33.3 |
| Day 253 | 531.03 ± 31.1 |
| Day 337 | 530.18 ± 41.3 |
| Day 421 | 594.32 ± 35.2 |
| Day 449 | 231.97 ± 48.6 |
Blood samples were collected for measurement of serum concentration of free C5 at specified timepoints. No study intervention administered on Day 449. A decrease indicated a reduction in disease activity.
| ug/mL | Eculizumab |
|---|---|
| Day 1 | -80.6911 ± 21.2241 |
| Day 29 | -80.6911 ± 21.2241 |
| Day 85 | -80.6911 ± 21.2241 |
| Day 169 | -80.6911 ± 21.2241 |
| Day 253 | -80.6911 ± 21.2241 |
| Day 337 | -81.5460 ± 21.1775 |
| Day 421 | -82.2563 ± 21.3936 |
| Day 449 | -82.4700 ± 21.8728 |
Blood samples were collected for measurement of serum concentration of total C5 at specified timepoints. No study intervention administered on Day 449. A decrease indicated a reduction in disease activity.
| ug/mL | Eculizumab |
|---|---|
| Day 1 | -13.3422 ± 6.3902 |
| Day 29 | 49.5372 ± 15.2890 |
| Day 85 | 52.8607 ± 17.8070 |
| Day 169 | 50.9998 ± 17.9024 |
| Day 253 | 61.3600 ± 24.0315 |
| Day 337 | 60.9581 ± 24.3898 |
| Day 421 | 62.8651 ± 19.0970 |
| Day 449 | 64.4332 ± 22.4364 |
Blood samples were collected for measurement of treatment-emergent ADAs to eculizumab at specified timepoints.
| Participants | Eculizumab |
|---|---|
| Number of Participants With Treatment-emergent Antidrug Antibodies (ADAs) to Eculizumab | 0 |
The FACIT-Fatigue is a 13-item questionnaire that assesses self-reported fatigue and its impact upon daily activities and function over the preceding 7 days. The FACIT-Fatigue scale is a collection of quality of life (QoL) questionnaires pertaining to the management of fatigue symptoms due to a chronic illness. Participants scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). Total scores were calculated as the sum from all 13 items and ranged from 0 to 52, with higher scores indicating an increased QoL. Analysis was performed using a MMRM, including FACIT-Fatigue score change from baseline values at the scheduled visits from Week 1 to Week 12 as the dependent variable, with the fixed categorical effect of study visit, fixed continuous effect of baseline value of FACIT-Fatigue, and participant as random effect. Assessed at baseline, 1, 2, 3, 4, 6, 8, 10, and 12 weeks, Week 12 reported.
| score on a scale | Eculizumab |
|---|---|
| Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 12 | 5.6 (2.3 to 8.9) |
Breakthrough hemolysis was defined as at least 1 new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, shortness of breath \[dyspnea\], anemia \[hemoglobin \<10 grams/deciliter\], major adverse vascular event \[including thrombosis\], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2 times (\*) upper limit of normal (ULN), after prior LDH reduction to \<1.5\* ULN on therapy.
| percentage of participants | Eculizumab |
|---|---|
| Percentage of Participants With Breakthrough Hemolysis | 4.0 (0.1 to 20.4) |
Blood samples were collected for measurement of LDH at specified timepoints. LDH normalization was defined as LDH ≤ULN.
| percentage of participants | Eculizumab |
|---|---|
| Percentage of Participants Achieving LDH Normalization | 36.0 (18.0 to 57.5) |
Transfusion avoidance was defined as remaining transfusion free (that is, had not received any transfusion) and did not require transfusion as per protocol.
| percentage of participants | Eculizumab |
|---|---|
| Percentage of Participants Achieving Transfusion Avoidance | 96.0 (79.6 to 99.9) |
Blood samples were collected for measurement of LDH at specified timepoints.
| percentage of participants | Eculizumab |
|---|---|
| Percentage of Participants With LDH ≤1.5* ULN at Week 12 | 80.0 (59.3 to 93.2) |
Collected over Baseline through Week 64. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eculizumab | 1/25 (4%) | 9/25 (36%) | 21/25 (84%) |
| Event | Eculizumab |
|---|---|
| PneumoniaInfections and infestations | 3/25 |
| Complicated appendicitisInfections and infestations | 1/25 |
| EndocarditisInfections and infestations | 1/25 |
| Febrile infectionInfections and infestations | 1/25 |
| Hepatitis AInfections and infestations | 1/25 |
| InfluenzaInfections and infestations | 1/25 |
| Urinary tract infectionInfections and infestations | 1/25 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/25 |
| Cerebral infarctionNervous system disorders | 1/25 |
| Myocardial infarctionCardiac disorders | 1/25 |
| Event | Eculizumab |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 7/25 |
| HeadacheNervous system disorders | 5/25 |
| PyrexiaGeneral disorders | 4/25 |
| COVID-19Infections and infestations | 3/25 |
| HyperuricaemiaMetabolism and nutrition disorders | 3/25 |
| HypokalaemiaMetabolism and nutrition disorders | 3/25 |
| Neutrophil count decreasedInvestigations | 3/25 |
| H1N1 influenzaInfections and infestations | 2/25 |
| NasopharyngitisInfections and infestations | 2/25 |
| Hepatic function abnormalHepatobiliary disorders | 2/25 |
Full Analysis Set: all participants who received at least 1 dose of study intervention and had at least 1 efficacy assessment post first dose.
| Age, Continuous(years) | Eculizumab |
|---|---|
| Mean | 40.5 ± 13.4 |
| Sex: Female, Male(Participants) | Eculizumab |
|---|---|
| Female | 10 |
| Male | 15 |
| Ethnicity (NIH/OMB)(Participants) | Eculizumab |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 25 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Eculizumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 25 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Baseline Lactate Dehydrogenase (LDH)(U/L) | Eculizumab |
|---|---|
| Mean | 1657.50 ± 575.93 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jul 2023 to primary completion in Apr 2025, 21 months.
Results were first posted in Jun 2026, 1 year 1 month after primary completion.
Of 35 industry-sponsored phase 3 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's 21 months is close to that.
Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 15 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eculizumab
Alexion Pharmaceuticals, Inc. →